These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 34129638)

  • 41. Pandemic influenza (A/H1N1) vaccine uptake among French private general practitioners: a cross sectional study in 2010.
    Verger P; Flicoteaux R; Schwarzinger M; Sagaon-Teyssier L; Peretti-Watel P; Launay O; Sebbah R; Moatti JP
    PLoS One; 2012; 7(8):e41837. PubMed ID: 22879896
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An analysis of national target groups for monovalent 2009 pandemic influenza vaccine and trivalent seasonal influenza vaccines in 2009-10 and 2010-11.
    Ng S; Wu P; Nishiura H; Ip DK; Lee ES; Cowling BJ
    BMC Infect Dis; 2011 Aug; 11():230. PubMed ID: 21871096
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effectiveness of seasonal 2008-2009, 2009-2010 and pandemic vaccines, to prevent influenza hospitalizations during the autumn 2009 influenza pandemic wave in Castellón, Spain. A test-negative, hospital-based, case-control study.
    Puig-Barberà J; Arnedo-Pena A; Pardo-Serrano F; Tirado-Balaguer MD; Pérez-Vilar S; Silvestre-Silvestre E; Calvo-Mas C; Safont-Adsuara L; Ruiz-García M;
    Vaccine; 2010 Nov; 28(47):7460-7. PubMed ID: 20875486
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Influenza Vaccine Effectiveness in the Netherlands from 2003/2004 through 2013/2014: The Importance of Circulating Influenza Virus Types and Subtypes.
    Darvishian M; Dijkstra F; van Doorn E; Bijlsma MJ; Donker GA; de Lange MM; Cadenau LM; Hak E; Meijer A
    PLoS One; 2017; 12(1):e0169528. PubMed ID: 28068386
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effectiveness of the monovalent influenza A(H1N1)2009 vaccine in Navarre, Spain, 2009-2010: cohort and case-control study.
    Castilla J; Morán J; Martínez-Artola V; Fernández-Alonso M; Guevara M; Cenoz MG; Reina G; Alvarez N; Arriazu M; Elía F; Salcedo E; Barricarte A;
    Vaccine; 2011 Aug; 29(35):5919-24. PubMed ID: 21723358
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A hidden vulnerable population: Young children up-to-date on vaccine series recommendations except influenza vaccines.
    Bleser WK; Salmon DA; Miranda PY
    PLoS One; 2020; 15(6):e0234466. PubMed ID: 32555653
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Influenza vaccination coverage rates in five European countries during season 2006/07 and trends over six consecutive seasons.
    Blank PR; Schwenkglenks M; Szucs TD
    BMC Public Health; 2008 Aug; 8():272. PubMed ID: 18673545
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Low influenza vaccination rates among child care workers in the United States: assessing knowledge, attitudes, and behaviors.
    de Perio MA; Wiegand DM; Evans SM
    J Community Health; 2012 Apr; 37(2):272-81. PubMed ID: 21938550
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Influenza immunisation coverage from 2015 to 2017: A national study of adult patients from Australian general practice.
    De Oliveira Bernardo C; González-Chica DA; Chilver M; Stocks N
    Vaccine; 2019 Jul; 37(31):4268-4274. PubMed ID: 31253446
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Influenza epidemiology in Italy two years after the 2009-2010 pandemic: need to improve vaccination coverage.
    Gasparini R; Bonanni P; Amicizia D; Bella A; Donatelli I; Cristina ML; Panatto D; Lai PL
    Hum Vaccin Immunother; 2013 Mar; 9(3):561-7. PubMed ID: 23292210
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011/12.
    Castilla J; Martínez-Baz I; Martínez-Artola V; Reina G; Pozo F; García Cenoz M; Guevara M; Morán J; Irisarri F; Arriazu M; Albéniz E; Ezpeleta C; Barricarte A; ;
    Euro Surveill; 2013 Jan; 18(5):. PubMed ID: 23399423
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Public health and economic impact of seasonal influenza vaccination with quadrivalent influenza vaccines compared to trivalent influenza vaccines in Europe.
    Uhart M; Bricout H; Clay E; Largeron N
    Hum Vaccin Immunother; 2016 Sep; 12(9):2259-68. PubMed ID: 27166916
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pandemic influenza A H1N1 vaccine in recipients of solid organ transplants: immunogenicity and tolerability outcomes after vero cell derived, non-adjuvanted, whole-virion vaccination.
    Lagler H; Wenisch JM; Tobudic S; Gualdoni GA; Rödler S; Rasoul-Rockenschaub S; Jaksch P; Redlberger-Fritz M; Popow-Kraupp T; Burgmann H
    Vaccine; 2011 Sep; 29(40):6888-93. PubMed ID: 21803100
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Use of influenza A (H1N1) 2009 monovalent vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009.
    ;
    MMWR Recomm Rep; 2009 Aug; 58(RR-10):1-8. PubMed ID: 19713882
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interim influenza vaccine effectiveness: A good proxy for final estimates in Spain in the seasons 2010-2014.
    Jiménez-Jorge S; Pozo F; Larrauri A;
    Vaccine; 2015 Jun; 33(29):3276-80. PubMed ID: 25869892
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Barriers to influenza vaccine uptake in obese people in Italy: Changes 2005-2013.
    Barbadoro P; Recanatini C; Ponzio E; Illuminati D; D'Errico MM; Prospero E
    Eur J Intern Med; 2016 Oct; 34():34-38. PubMed ID: 27139917
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Estimating influenza vaccine effectiveness in Spain using sentinel surveillance data.
    Jimenez-Jorge S; de Mateo S; Delgado-Sanz C; Pozo F; Casas I; Garcia-Cenoz M; Castilla J; Rodriguez C; Vega T; Quinones C; Martinez E; Vanrell JM; Gimenez J; Castrillejo D; Altzibar JM; Carril F; Ramos JM; Serrano MC; Martinez A; Torner N; Perez E; Gallardo V; Larrauri A;
    Euro Surveill; 2015 Jul; 20(28):. PubMed ID: 26212144
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vaccine effectiveness against influenza A(H3N2) and B among laboratory-confirmed, hospitalised older adults, Europe, 2017-18: A season of B lineage mismatched to the trivalent vaccine.
    Rose AMC; Kissling E; Gherasim A; Casado I; Bella A; Launay O; Lazăr M; Marbus S; Kuliese M; Syrjänen R; Machado A; Kurečić Filipović S; Larrauri A; Castilla J; Alfonsi V; Galtier F; Ivanciuc A; Meijer A; Mickiene A; Ikonen N; Gómez V; Lovrić Makarić Z; Moren A; Valenciano M;
    Influenza Other Respir Viruses; 2020 May; 14(3):302-310. PubMed ID: 32022450
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Enhanced passive surveillance of influenza vaccination in England, 2016-2017- an observational study using an adverse events reporting card.
    de Lusignan S; Ferreira F; Damaso S; Byford R; Pathirannehelage S; Yeakey A; Yonova I; Schuind A; Dos Santos G
    Hum Vaccin Immunother; 2019; 15(5):1048-1059. PubMed ID: 30648923
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Technical guidelines for seasonal influenza vaccination in China, 2019-2020].
    National Immunization Advisory Committee (NIAC) Technical Working Group (TWG), Influenza Vaccination TWG
    Zhonghua Liu Xing Bing Xue Za Zhi; 2019 Nov; 40(11):1333-1349. PubMed ID: 31838802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.